An update from Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H ( (HK:9989) ) is now available.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. announced that its enoxaparin sodium injection, Ivenoxin, has received approval from the South African Health Products Regulatory Authority for sale in South Africa. This approval enhances the company’s global market share and demonstrates its capability to penetrate overseas markets. The company plans to continue its international expansion and strengthen its sales channels worldwide.
More about Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. is a pharmaceutical company based in China, specializing in the production of enoxaparin sodium injections. The company focuses on expanding its market presence globally, with products approved in over 50 countries, including major markets such as China, the United States, and the European Union.
YTD Price Performance: 11.11%
Average Trading Volume: 3,890,561
Technical Sentiment Signal: Sell
Current Market Cap: HK$15.5B
See more data about 9989 stock on TipRanks’ Stock Analysis page.